Measles, mumps, and rubella are viral diseases that may adversely affect nonimmune pregnant women and their fetuses/neonates. Prevention of these diseases and their complications can be achieved through measles-mumps-rubella (MMR) vaccination before pregnancy. The vaccine is contraindicated during pregnancy, because it contains live, attenuated viruses that pose a theoretical risk to the fetus. However, accidental receipt of MMR vaccination is not known to cause maternal/fetal complications. MMR immunization is recommended to nonimmune obstetric patients upon completion or termination of pregnancy.
Introduction
Measles, mumps, and rubella are vaccinepreventable, viral diseases that have the potential to harm nonimmune pregnant women and their fetuses/neonates if exposure occurs. [1] [2] [3] [4] [5] [6] [7] [8] [9] The most concerning of these is rubella, as it can cause congenital rubella syndrome (CRS) with devastating effects. 3, 4, 6, 7 In this review, we consider each of the diseases in turn and address the role of vaccination in preventing these diseases and their complications.
Measles

ETIOLOGY
Measles, or rubeola, is an RNA virus, belonging to the Morbillivirus genus, which is in the Paramyxoviridae family. 1, 5 Humans are the only natural host of this highly contagious virus.
EPIDEMIOLOGY
Measles is transmitted through droplet nuclei. In temperate regions, the incidence is highest in late winter and spring. 1, 4, 5 Reports of measles cases in the United States have dramatically declined since the prevaccine era. In 2000, the Centers for Disease Control and Prevention (CDC) declared that measles was eliminated from the United States, although outbreaks resulting from foreign travel still occur. 10 From January to September 2011, 15 measles outbreaks with 211 confirmed cases were reported in the United States, the highest number since 1996. Of the 211, 18% occurred among individuals who received at least 1 measles-mumpsrubella (MMR) vaccine dose. Until measles is eradicated, outbreaks will continue in the United States and worldwide. Currently, over 20 million measles infections occur worldwide annually, with 164,000 deaths in 2008 alone. 1 
POPULATIONS SUSCEPTIBLE TO EXPOSURE
The risk of exposure is higher for certain populations. 1, 4 For instance, epidemics still occur, typically in developing countries without mass vaccination programs. Close contact with nonvaccinated individuals from these countries (eg, airports, clinics, and hospitals) increases the chance of exposure among nonimmune individuals.
Measles is thought of as a childhood disease, but demographics have shifted. 1, 4 Since 2001, half of the reported cases in the United States were in those 20 years and older. Although outbreaks are rare in the United States, an individual case could lead to an outbreak due to the high transmissibility of the virus. Obstetrical care providers should be aware of any reported measles cases in the area and, if so, monitor nonvaccinated obstetric patients closely for both exposure to measles and its clinical manifestations.
CLINICAL MANIFESTATIONS
Measles transmission occurs by droplet nuclei. 1, 4, 5, 8 Communicability lasts approximately 8 days. The prodromal stage occurs 10 to 12 days after exposure and is characterized by 2 to 3 days of fever, anorexia, and malaise combined with the triad of cough, conjunctivitis, and coryza. 1, 4, 5 Toward the end of the prodromal stage, Koplik spots, an enanthem comprising blue-white spots, appear on the buccal surfaces of the mouth and last 12 to 18 hours. 1, 5, 8 They are pathognomonic of measles infection. 1, 5 The prodromal phase is followed by the appearance of a maculopapular, erythematous rash, accompanied by a high fever. The rash occurs anywhere from 1 or 2 days before to 1 or 2 days after the Koplik spots appear, lasting 5 to 6 days in toto. 1 The rash begins (and disappears) on the head and face, expanding outwards and downwards, eventually reaching the hands and feet. A persisting cough characterizes the convalescent stage, which may persist up to 1 to 2 weeks after the rash resolves. 5 Measles-induced complications affect approximately 30% of infected individuals, especially young children (ages below 5) and adults (ages above 20). 1, 4 The most commonly reported complications are diarrhea (8%), otitis media (7%), and pneumonia (6%). 1, 4, 5, 8 The leading cause of death in adults is acute encephalitis, a rare complication of measles (0.1%). 1, 4 Historical data suggest that complications are more severe in pregnant women. 5 
COMPLICATIONS IN THE OBSTETRIC PATIENT AND HER OFFSPRING DUE TO INFECTION
Measles exposure during pregnancy may cause adverse maternal and fetal effects. 1, 4, 5, 8, 9 In a CDC study, 58 pregnant women with active measles infection were followed to assess measles-induced maternal and fetal effects. 9 Fifteen of the 58 women developed pneumonia, of which 2 died. The most common fetal/neonatal effect observed was premature delivery (13 of 58). In addition, 5 pregnancies resulted in spontaneous abortion. Measles
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has not been proven to cause birth defects. 1, 4, 5, 8 If a nonimmune pregnant patient is exposed to measles just before delivery, in utero and intrapartum viral transmission is likely to cause a serious infection in the neonate. 5 The risk can be reduced with passive immunization (see postexposure interventions).
DIAGNOSIS OF INFECTION
One confirms diagnosis with a seropositive antibody response using a serological assay and detection of measles in clinical specimens (eg, urine, nasopharyngeal secretions, throat swabs, or blood) by viral culture. 1, 4, 5 Blood samples for serological assays should be drawn at the same time as the collection of clinical specimens; however, clinical specimens should be collected not later than 7 to 10 days after the rash onset. 1 Serological assays [eg, enzyme-linked immunosorbent assays (ELISA) and hemagglutination inhibition assays] that measure IgM titers can be performed in a medical laboratory, although the most reliable serological assay is an IgM capture assay developed and performed by the CDC. 1, 4 The IgM capture assay can only be performed within 72 hours after rash onset, whereas serological tests performed in a medical laboratory at a hospital or medical facility can detect IgM 1 to 2 months after the onset of symptoms. Because of the high transmissibility of measles, virus isolation of clinical specimens from individuals suspected of measles exposure is performed by the state public health laboratory or the CDC. 1 
POSTEXPOSURE INTERVENTIONS
Immune globulin is a recommended prophylaxis for nonimmune, exposed obstetric patients as long as treatment is received not >6 days after exposure. 1, 4, 5 Immune globulin is administered intramuscularly at 0.25 mL/kg (maximum dose = 15 mL, given at 2 injection sites). It will not prevent measles but may suppress the measles-induced symptoms until the MMR vaccination can be administered upon completion or termination of pregnancy. In addition, if the maternal infection is close to parturition, immune globulin may reduce the risk of the neonate developing measles. Otherwise, treatment for measles in the obstetric patient is limited to symptomatic care. 5 Mumps ETIOLOGY Mumps, like measles, is a disease caused by an RNA virus classified in the Paramyxoviridae family. 2, 5, 8 Unlike measles, mumps belongs to the Rubulavirus genus. It is a human disease with no animal reservoirs.
EPIDEMIOLOGY
Mumps cases can occur at any time of the year with peak incidences during winter and spring. 2, 5 Although reports of mumps cases in the United States have declined by >90% since the prevaccine era (212,000 reported cases in 1968), mumps outbreaks still occur in the United States and worldwide. The largest mumps outbreak in decades occurred through the Midwest in 2006 (6584 cases) followed by outbreaks along the East Coast and Canada in 2009 to 2010 (3502 cases). Among those for whom records were available in the 2009 to 2010 outbreak, 90% had received at least 1 dose of mumps-containing vaccine. 2, 11 
POPULATIONS SUSCEPTIBLE TO EXPOSURE
Mumps viral transmission occurs through contact with droplets of saliva or mucus from the mouth, nose, or throat of an infected person, anywhere from 3 days before to 4 days after the onset of parotitis, the disease's hallmark characteristic. 2, 4 However, infected individuals lacking classic symptoms also have the potential to transmit mumps to people susceptible to exposure.
Although individuals from countries without routine immunization against mumps are more likely to import mumps to the United States, internationally imported mumps cases in the United States are also possible from countries with routine mumps immunization programs. 2, 4, 11 For instance, an 11-year-old boy with mumps traveling from the United Kingdom in 2009 transmitted the disease to people susceptible to exposure in New York, eventually spreading across the East Coast and into Canada. 1, 11 Over half (53%) of the reported cases from this multistate outbreak involved school-aged children (ages, 5 to 17). This is likely due to their close and consistent contact at school. Students exempted from receiving the MMR vaccine because of medical, religious, or philosophical reasons or because their parents fear the MMR vaccine causes autism are at a higher risk for exposure to mumps. Mumps transmission is also promoted by other areas where people may congregate, including airports, urban areas, colleges, and large households. 1, 4, 5 
CLINICAL MANIFESTATIONS
A prodromal stage appears 14 to18 days after exposure and occurs before parotitis develops. This prodromal stage includes nonspecific symptoms of malaise, myalgia, headache, low-grade fever, and anorexia. 2 As many as 40% to 50% of the infected population have only nonspecific symptoms. Another 20% are asymptomatic. The remaining infected population is at risk for developing parotitis, which can be unilateral or bilateral. Salivary gland inflammation decreases after 1 week with full recovery by 10 days. 2 Complications include aseptic meningitis (r15%), pancreatitis (2% to 5%), oophoritis (5%), meningoencephalitis (1/ 50,000 cases), and deafness (1/20,000 cases). 1 
COMPLICATIONS IN THE OBSTETRIC PATIENT AND HER OFFSPRING DUE TO INFECTION
Unlike measles, pregnancy does not appear to affect severity of mumps, 5 but if exposure occurs during the first trimester, the patient has a higher risk of spontaneous abortion. 4, 5, 8 Spontaneous abortion has been found to occur in 27% of pregnant women exposed to mumps during their first trimester compared with 13% of controls. 8 There are no associated congenital malformations in children whose mothers were exposed to mumps at any time during pregnancy. 2, 4, 5, 11 
DIAGNOSIS OF INFECTION
A laboratory diagnosis of mumps may be needed if exposure to mumps is suspected. Mumps can be diagnosed by isolating the virus from a cultured swab of one of the inflamed salivary glands, particularly the parotid duct. 2, 4, 5 Mumps may also be diagnosed from a buccal or throat swab using polymerase chain reaction. 2, 4 A commonly used, simple, and sensitive means to diagnose mumps infection is by measuring IgM or IgG titers using a serological test (eg, ELISA). 2, 5 IgM titers are useful during the initial period of the illness but are often not detectable in individuals with 1 or more doses of mumps-containing vaccine. IgG titers are useful from a time between the exanthema and the recovery phase of infection to years after infection. False negatives are possible, and therefore, diagnosis should not be necessarily dismissed if the exposure has not been laboratory Measles, Mumps, and Rubella 553 confirmed but parotitis and other common mumps manifestations are observed.
POSTEXPOSURE INTERVENTIONS
Treatment for mumps infection is limited to symptomatic relief. 5 Rubella ETIOLOGY Rubella, or German measles, is an RNA virus in the genus Rubivirus within the Togaviridae family. 3, 6 It is a human disease with no animal reservoirs.
EPIDEMIOLOGY
The incidence of rubella cases is highest from late winter to early spring. 3 The number of rubella cases has progressively declined in the United States since the prevaccine era due to mass immunization programs and, as of 2004, is no longer endemic. 3 Rubella remains endemic in other countries with a dramatic increase in cases reported during 2009 versus during 2000. 12 The World Health Organization reported that rubella cases in the African Region and the South-East Asian Region alone increased from 865 to 17,388 and from 1165 to 17,208 during 2000 and 2009, respectively. These regions represent a significant number of the 121,344 global cases of rubella reported by the World Health Organization during 2009; neither region has any specific goals to control rubella outbreaks. Rubella eradication will not be possible unless global immunization policies (eg, immunization registries) are implemented and enforced.
POPULATIONS SUSCEPTIBLE TO EXPOSURE
The majority (71% as of 2003) of rubella cases in the United States are currently among individuals of child-bearing ages (ages, 15 to 39). 3, 4 This shift in demographics from a classic childhood disease increases the probability of CRS development should a rubella outbreak occur. Rubella cases reported in the United States presently involve a high proportion of Hispanic-born young adults from countries lacking routine administration of rubella-containing vaccines. Consequently, the majority of CRS cases reported in the United States since 1997 are among infants and children born to foreign-born women from Latin American and Caribbean countries. 3 Transmission occurs through contact with droplets from infected individuals during the last week of the 2-to 3-week incubation period, until a week after development of the stereotypic rubella rash. 3, 6 Individuals with asymptomatic or subclinical infections may also transmit the disease. In addition, infants with CRS shed large quantities of the rubella virus from their bodily secretions for more than a year postparturition and are highly contagious. Nonimmune pregnant women in close contact with infected individuals are at risk for acquired rubella infection, and their offspring may develop rubella-induced complications.
CLINICAL MANIFESTATIONS
Acquired rubella infection may be asymptomatic or subclinical in up to half of those exposed, especially in children. 3, 4, 6 Of the people who clinically manifest the disease, symptoms are mild and self-limiting. A prodromal stage of 1 to 5 days is represented by a low-grade fever, malaise, lymphadenopathy, and an upper respiratory infection. Forchheimer spots (petechiae on the soft palate) may precede or accompany the rash. 3, 6 The rash is mild and maculopapular, beginning on the face and extending downwards; it occurs approximately 14 to 17 days after exposure and typically lasts 3 days.
Rubella frequently leads to arthralgia/ arthritis in women (up to 70%). Although joint symptoms, along with conjunctivitis, are more common complications in the obstetric patient, encephalitis (1/6000 cases) may develop, affecting female adults more frequently than men or children. 3, 4 
COMPLICATIONS IN THE OBSTETRIC PATIENT AND HER OFFSPRING DUE TO INFECTION
Although acquired rubella infection is generally mild, transplacental passage of the virus to the embryo/fetus during maternal viremia (5 to 7 d after exposure) can cause devastating consequences (ie, CRS). 3, 4, 6 Virus transmission with maternal reinfections are rare. 6 CRS symptoms include, but are not limited to, fetal death, spontaneous abortion, premature delivery, ocular abnormalities (eg, cataracts and microophthalmia), neurological problems (eg, intellectual disability), abnormal cardiac development and, most commonly, deafness. Congenital malformations may be present at birth or sometimes develop months to years after birth. 3, 4, 6 Examples of delayed CRSinduced maladies are type I diabetes mellitus, deafness, intellectual disability, subacute encephalitis.
The frequency and severity of CRS decreases as gestation progresses. 3, 4, 6 For example, maternal exposure to rubella during the first 12 weeks of pregnancy results in CRS in 85% of developing embryos/fetuses. Conversely, by the 20th gestational week, the risk of congenital defects is minimal. Nevertheless, neonatal rubella infections are possible when nonimmune mothers transmit rubella to the fetus close to delivery. 6 
DIAGNOSIS OF INFECTION
If exposure to rubella is suspected in a nonimmune obstetric patient, laboratory diagnosis is necessary immediately, even if clinical manifestations are not present. 3, 4, 6 Isolation of rubella with cultured throat or nasal specimens provides an accurate diagnosis of rubella, although it is a labor-intensive process. 3, 6 A serological assay (ELISA) can be easily and quickly performed to detect the presence rubella-specific antibodies. IgM is detectable within 7 to 10 days after the initial exanthema. 3 False positives may occur if the patient has a positive Rh factor, is infected with parvovirus, or has a positive heterophile test for infectious mononucleosis. 3, 4, 6 A total of 7 to 21 days after the first ELISA, one should obtain an additional ELISA to confirm the diagnosis. Infection is confirmed by a positive IgM, a 4-fold rise in IgG, or a positive culture.
If the obstetric patient is positive for rubella infection, rubella may be diagnosed in the fetus by collecting either a specimen of amniotic fluid, cord blood, or placental tissue by amniocentesis, cordocentesis, or chorionic villus sampling (respectively) for use in laboratory assays including polymerase chain reaction, fluorescence, in situ hybridization, or ELISA (to quantify rubella-specific IgM). 13 Obstetrical care providers can use the information gained from one of these methods to monitor the fetus closely for distress and the presence of any congenital defects associated with CRS. Ultrasound diagnosis alone on an infected fetus would be difficult due to the spectrum of abnormalities possible.
POSTEXPOSURE INTERVENTIONS
There is no specific pharmacological treatment for acquired rubella infection. 3, 4, 6 Intramuscular administration of immune globulin (20 mL, given at 2 injection sites) within 72 hours of exposure may be administered to the obstetric patient to suppress, but not eliminate, symptoms. 4, 6 Infants with CRS have been Measles, Mumps, and Rubella 555 born to women who received immune globulin therapy soon after exposure. Therefore, it is not a routine prophylaxis and should only be administered if the patient chooses not to terminate her pregnancy. Otherwise, treatment is limited to symptomatic relief. 6 Prevention With MMR Vaccination
BACKGROUND
The MMR (M-M-R-II; Merck, Whitehouse Station, NJ) vaccine is recommended by the Advisory Committee on Immunization Practices, the American Congress of Obstetricians and Gynecologists, the American Academy of Pediatrics, and the American Academy of Family Physicians for routine use in the prevention of measles, mumps, and rubella. 14, 15 The combination is as effective as the formerly available monovalent forms: measles (ATTENUVAX), mumps (MUMPSVAX), and rubella (MERUVAX) vaccines (Merck). [14] [15] [16] The trivalent vaccine reduces the number of injections from 3 to 1 in a 2 dose series, avoids unnecessary delays and the problems of spacing live, attenuated vaccines, and protects against all 3 diseases simultaneously. 15, 16 There is no medical reason to favor separate vaccination over the combination vaccine. These reasons, along with manufacturing constraints, prompted Merck to discontinue production of monovalent ATTENUVAX, MUMPSVAX, and MERUVAX in 2008. 15 The M-M-R-II vaccine contains live, attenuated viruses for measles (Edmonston-Enders viral strain), mumps (Jeryl Lynn viral strain), and rubella (Wistar RA 23/7 viral strain). [1] [2] [3] [4] 14 The MMRV vaccine (ProQuad), which includes a vaccine against the Varicella virus or chicken pox, was introduced in 2005 but is not recommended for individuals over 13 years of age. [1] [2] [3] 
DOSAGE AND SCHEDULE
The M-M-R II vaccine is supplied as a single-dose vial. 4, 14 It must be kept cool and out of light because of the live, attenuated viruses' instability to heat and light. [1] [2] [3] [4] 14, 16, 17 When reconstituted, it must be used within 8 hours or discarded. Upon reconstitution, 0.5 mL of the vaccine is administered subcutaneously, usually in the outer region of the upper arm. 4, 14, 17 The Advisory Committee on Immunization Practices recommends an immunization schedule to maximize the time of protection against measles, mumps, and rubella infection by minimizing the time between interference of maternal antibodies and receipt of MMR vaccine. 16 Although the current recommended schedule is to receive the first dose at 12 to 15 months followed by the second dose at 4 to 6 years (before elementary school enrollment), vaccine status should be assessed at every medical encounter and individuals due for a dose of MMR vaccine should receive the vaccine at that time. [1] [2] [3] [4] [5] [6] 14, 17 Receipt of the 2dose MMR series is strongly advised for eligible, nonpregnant women at least 28 days apart with completion not <1 month before conception. [1] [2] [3] [4] [5] [6] [7] 18 Counseling is recommended to discuss both the importance of not becoming pregnant for at least 28 days after the MMR vaccine series because of the theoretical risk posed by the live albeit attenuated vaccine viruses. 4, 6, 18 
ACCIDENTAL MMR RECEIPT DURING PREGNANCY
The possibility of transmitting a live, attenuated virus to the fetus during pregnancy and the concomitant consequences of that virus on the developing fetus is a theoretical (but never demonstrated) concern in vaccinating pregnant or soonto-be pregnant women with the MMR vaccine. [1] [2] [3] [4] [5] [6] [7] 16, 18 The theoretical risk for fetal complications arising from MMR vaccination is 1.6%. 3, 6 From 1971 to 1989, the CDC maintained the Vaccine in Pregnancy Registry to document women who were vaccinated before or during pregnancy and to monitor any complications. 3, 4, 6 The registry consisted of 321 pregnant women (full term). Among these women, there was no evidence of MMRinduced congenital defects. With the absence of observed risk, the CDC does not recommend termination of pregnancy if inadvertent vaccination occurs. [1] [2] [3] [4] 6, 7 However, individual counseling is recommended to educate women of the realtheoretical but low-theoretical risk. 3, 7, 18 
EVIDENCE OF IMMUNITY
The standard of care in the United States is to ascertain the seroconversion rate of rubella, although not measles or mumps, during early prenatal care through serological assays. 4, 6, 7 If the patient is found to be nonimmune to rubella, the MMR vaccine is recommended upon completion or termination of pregnancy and before discharge from the medical facility. 3, 4, 6 Breastfeeding is not a contraindication to MMR vaccination. [1] [2] [3] [4] 16 Postpartum MMR vaccination while breastfeeding will not alter the infant's immunization schedule.
If the MMR vaccine was not administered before pregnancy and/or the pregnant woman was seronegative for rubella antibodies, then potential exposure may be minimized for the pregnant woman by washing hands frequently with soap and water, minimizing close contact with those who are ill with viral-like conditions, and avoiding travel to countries where rubella is still endemic. In addition, household contacts should receive the MMR vaccine to provide a measure of protection for mother and unborn child until she is able to be vaccinated. 3 
REACTOGENICITY
The MMR vaccine is safe and well tolerated. [1] [2] [3] [4] 14 Common adverse effects are typically mild and include a fever (Z103 1F; 5% to 15%), which begins 5 to 12 days after vaccination and lasts several days, arthritis (10%), arthralgia (25%), and a rash (5%). [1] [2] [3] [4] [5] [6] 17 Thrombocytopenia (<1/30,000 doses) and encephalitis/encephalopathy (1/ 1,000,000 doses) are severe adverse effects but are very rare. [1] [2] [3] 7, [16] [17] [18] As mentioned, the MMR vaccine is contraindicated in pregnant women and women trying to conceive. [1] [2] [3] [4] [5] [6] [7] 16 The MMR vaccine is also contraindicated in those with a history of a severe allergy to vaccine additives (neomycin and gelatin), previous hypersensitivity reaction to MMR/MMRV vaccine, moderate or severe acute febrile illness, altered immunocompetence (immune deficiency diseases, leukemia, lymphoma, generalized malignancy, or receiving therapy with corticosteroids, alkylating drugs, antimetabolites, or radiation), receipt of antibodycontaining blood products (IG, IVIG, specific IG) r2 weeks before vaccine or r3 months after vaccine, and a personal history of seizures of any etiology. [1] [2] [3] [4] 14, 15, 17, 18 Exceptions to patients with altered immunocompetence are: HIV patients (dependent on level of immunosuppression); patients with leukemia remission and no chemotherapy for Z3 months; and steroid use is <2 weeks, in a low to moderate dose, as a replacement therapy or administered through topical, intra-articular, bursal, or tendon injection. 14, 16, 18 
IMMUNOGENICITY AND EFFICACY
The MMR vaccine is immunogenic and effective against measles, mumps, and rubella infections and offers long-term immunity for many people who receive 2 recommended doses. [1] [2] [3] [4] [5] [6] Vaccine failure, either primary (failure to seroconvert) or secondary (waning immunity), is chiefly responsible for the susceptibility to measles, mumps, and/or rubella exposure, despite Measles, Mumps, and Rubella 557 MMR vaccination. Issues regarding primary vaccine failure have been largely addressed by implementing the 2 MMR dose schedule. [1] [2] [3] [4] In fact, the measles component of the MMR vaccine is effective in 95% to 98% of individuals after 1 dose and >99% after 2 doses. 1, 4, 5 Vaccine efficacy against rubella is similar to measles with a >95% seroconversion rate after 1 dose and >99% after 2 doses. 3, 4, 6 The mumps component of the MMR vaccine is the least effective of the 3 live, attenuated viruses with 64% to 95% seroconversion after 1 dose and 88% to 95% seroconversion after 2 doses. 2, 4 In infants, the timing of the first MMR dose may also affect efficacy against the measles component of the MMR vaccine if administered 12 to 14 months versus Z15 months of age, because passive immunity against measles is likely to persist shortly beyond 12 months. 4, 17 Over time, vaccine efficacy against measles, mumps, and/or rubella may decline for some people due to waning immunity. [1] [2] [3] [4] For instance, rubella immunity has been shown to decline after only 12 years, regardless of receiving the second MMR dose at ages 4 to 6 or 9 to 11. 19 Specifically, 1% of children (n = 307) remained seronegative at 1 month after the second MMR vaccine was administered as opposed to 10% of children who were seronegative 12 years later. In addition, measles immunity persists in approximately 80% of adults immunized as a child. 8 However, the remaining 20%, including women of child-bearing age, are at risk for measles exposure and the associated consequences. Hence, the MMR vaccine is not foolproof for all pregnant patients due to primary and secondary vaccine failure.
STRATEGIES TO IMPROVE MMR VACCINATION AMONG NONIMMUNE FEMALES
Improvements of MMR vaccine strategies among females of child-bearing ages are needed to prevent development of CRS, especially for foreign-born females from countries without national immunization schedules. 3, 20 Some of these strategies could include offering the MMR vaccine to eligible, nonvaccinated females at family planning and sexually transmitted disease clinics, at the workplace (eg, hospital staff, military personnel, and teachers), and at college/university campuses. Furthermore, vaccine advocacy and education are important to expose vaccine truths from myths and to explain the consequences of not vaccinating, emphasizing the harmful and sometimes life-threatening fetal effects after maternal exposure to rubella, along with measles and mumps.
